IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

May 6, 2026

Meeting Format: Virtual

Time: 9:30 a.m. – 1:30 p.m.

Teams Meeting: https://teams.microsoft.com/meet/232633913604699?p=lcy7owV5z6Q3wb5B5M
Meeting ID: 232 633 913 604 699
Passcode: sV2bU3Xj

Tentative Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of February 4, 2026 Meeting Minutes
    b) February 2026 DUR Recommendation Letter to DHHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Wellpoint Iowa
    b) Fee-for-Service
    c) Iowa Total Care
    d) Molina Healthcare
    e) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be in-person or virtual testimony. Five (5) minute maximum limit.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CT April 29, 2026.**
    - **Send to pba_iadur@optum.com. Indicate if providing written or verbal comment.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Adherence to Antipsychotic Medications in Patients with Schizophrenia
        ii. Evaluation of the use of Duplicate Therapy for Autoimmune Disorders
    b) Proposal(s)
        i. Extended-Release ADHD Stimulants in Children Younger than 6 Years
        ii. CGRP Antagonist Duplicate Therapy
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization
    a) Apolipoprotein C-III (ApoC-III) Inhibitors
    b) Biologicals for Hidradenitis Suppurativa
    c) Dupilumab (Dupixent)
    d) Idiopathic Pulmonary Fibrosis and Related Lung Diseases
9. Miscellaneous

a) DUR Digest Vol. 38, No. 2 – First Review

10. MedWatch
    FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
    FDA Launches New Adverse Event Look-Up Tool
    FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa
    FDA approves drug for pediatric patients with most common form of dwarfism
    FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay in your comments being considered until the next scheduled meeting. Reference complete public comment policy here.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
August 5, 2026
Meeting Format: Hybrid
Location: Lucas State Office Building, Ground Floor, Assembly Room LG20-B,
321 E 12th St., Des Moines, IA 50319